Shire Boosts Eye Business with $160 Million SARcode Buy

25.03.2013 - Shire is to buy privately owned U.S. biotech firm SARcode Bioscience, paying $160 million upfront to win rights to a new drug in late-stage development for dry eye diseases. The...